Financial Performance - Total revenue for the six months ended September 30, 2022, was HKD 236.8 million, an increase of 25.1% compared to HKD 189.4 million for the same period in 2021[5]. - Profit attributable to equity holders increased by 114.8% to HKD 21.6 million, with a profit margin of 9.1% compared to 5.3% in the prior year[5]. - Adjusted EBITDA rose by 44.2% to HKD 56.7 million, with an adjusted EBITDA margin of 23.9%, up from 20.8%[5][7]. - Total revenue for the first half of fiscal year 2023 reached HKD 236.8 million, a 24% increase compared to HKD 189.4 million in the same period of fiscal year 2022[28]. - Revenue from the brand Chinese medicine segment was HKD 163.0 million, accounting for 69% of total revenue, reflecting a 7% increase from HKD 106.5 million in the previous year[28]. - Total revenue increased by HKD 47.4 million or 25.0% compared to the mid-term of the 2022 fiscal year, driven by a significant increase in the revenue of the Chinese medicine segment by HKD 56.5 million[29]. - The company reported a significant increase in revenue, achieving a total of HKD 1.2 billion for the first half of 2022, representing a 25% year-over-year growth[163]. Revenue Segmentation - Brand Chinese medicine revenue increased by 53.2% to HKD 163.1 million, while brand drugs revenue decreased by 10.3% to HKD 56.9 million[5]. - The brand pharmaceutical division reported a revenue decline of 10.3% during the reporting period, primarily due to weak retail performance in Hong Kong and Macau[19]. - Revenue from health supplements decreased by 13.3%, attributed to a decline in sales across various products in the Hong Kong retail sector[29]. - Revenue from mainland China surged to HKD 57,684,000, a significant increase from HKD 18,473,000 in the previous year, marking a growth of 212%[131]. Profitability and Margins - Gross profit for the period was HKD 85.5 million, representing a gross margin of 36.1%, down from 39.6% in the previous year[5]. - Operating profit surged by HKD 17.5 million or 112.2% to HKD 33.1 million, driven by increased gross profit and government employment support[39]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[163]. Assets and Liabilities - Total assets as of September 30, 2022, were HKD 1.34 billion, a slight increase of 0.4% from HKD 1.33 billion[6]. - Total liabilities decreased by 2.4% to HKD 354.4 million, down from HKD 363.3 million[6]. - Total equity increased by 1.4% to HKD 982.8 million, compared to HKD 969.2 million at the end of the previous period[6]. Market Position and Strategy - The company aims to enhance its brand management and product portfolio to establish a sustainable regional platform for healthcare products in Asia[12]. - The company has established a solid local distribution network and partnerships with selected product manufacturers to strengthen its market position[12]. - The company is focused on leveraging its unique advantages to solidify its competitive position as a forward-looking healthcare company in Asia[20]. - The company plans to continue collaborating with new and existing e-commerce platforms to explore market opportunities, supported by a strengthened team in mainland China and Hong Kong[20]. Product Development and Innovation - The company is actively expanding its online education programs to promote the importance of regular eye health check-ups and the clinical benefits of AIM Myopia Control Eye Drops[19]. - The company plans to continue expanding its product offerings, including new health supplements based on traditional Chinese medicine[1]. - Investment in R&D has increased by 15%, focusing on developing innovative health products to enhance market competitiveness[163]. Marketing and Consumer Engagement - Strong advertising and promotional activities have been launched to enhance brand recognition and consumer demand for the He Ji Gong brand[19]. - The company has initiated a new marketing strategy, increasing digital advertising spend by 20% to boost brand awareness and customer acquisition[163]. Sustainability and Corporate Responsibility - The company has implemented measures to encourage environmental sustainability, with no significant environmental impact reported[66]. - Future guidance indicates a focus on sustainability initiatives, with plans to reduce operational carbon footprint by 25% over the next five years[163]. Shareholder Information - The interim dividend declared for the six months ending September 30, 2022, is HKD 0.5 per ordinary share, totaling approximately HKD 4.5 million, compared to zero for the same period last year[76]. - The company has not reported any changes in the interests of directors or key executives in the company's shares since the last annual report[79]. Compliance and Governance - The audit committee consists of three independent non-executive directors, responsible for overseeing the integrity and accuracy of the company's financial statements[74]. - The financial report was reviewed and found to comply with Hong Kong Accounting Standards[98].

Financial Performance - Total revenue for the fiscal year ended March 31, 2022, was HKD 406,139,000, representing a 2.3% increase from HKD 397,158,000 in the previous year[15]. - The revenue from branded Chinese medicine increased by 10.5% to HKD 232,908,000, while branded pharmaceuticals decreased by 0.1% to HKD 134,330,000[15]. - Gross profit decreased by 18.6% to HKD 161,510,000, with a gross margin of 39.8%, down from 50.0%[15]. - Adjusted EBITDA fell by 29.0% to HKD 89,208,000, with an adjusted EBITDA margin of 22.0%, down from 31.7%[15][16]. - Profit attributable to equity holders increased by 8.9% to HKD 24,620,000, resulting in a profit margin of 6.1%, up from 5.7%[15]. - Total assets decreased by 3.5% to HKD 1,332,489,000, while total liabilities decreased by 16.3% to HKD 363,299,000[15]. - Total equity increased by 2.3% to HKD 969,190,000[15]. Market and Product Development - The company achieved revenue growth despite challenges, focusing on opportunities in the Chinese market[20]. - New product launches remain a priority development strategy, supported by close collaboration with global partners[20]. - The healthcare product portfolio includes leading brands that showed strong momentum, particularly AIM eye drops and Oncotype DX®[27]. - AIM eye drops have established a leading brand position in myopia control for children, supported by clinical research and professional recommendations[28]. - The company is expanding its product offerings, including the launch of the first extension product under the Wei Xian - U brand, which has received positive market feedback[31]. - The company has launched over 60 products on Tmall, with more than 55 and 35 products available on Tmall and JD's cross-border flagship stores respectively[31]. - The health care products segment experienced a decline in sales by 24.9%, primarily due to reduced consumer demand for infection prevention products[54]. - The company is developing new concentrated Chinese medicine granules and launching herbal-based supplements to meet growing consumer demand[65]. Strategic Initiatives - The company aims to build a product portfolio that anticipates market demand and motivates employees to excel[19]. - Strategic priorities include building a robust foundation, delivering more results, and motivating employees to pursue excellence[20]. - New partnerships in the brand drug and nutritional supplement categories are expected to contribute to short-term and long-term business growth[22]. - The company aims to strengthen its operational position and business platform through a multi-faceted growth strategy, addressing evolving market trends and consumer needs[31]. - The company is committed to responsible operations and enhancing environmental, social, and governance performance[23]. Corporate Governance - The company has complied with all provisions of the corporate governance code during the reporting period[111]. - The board consists of seven members, including one executive director, three non-executive directors, and three independent non-executive directors[114]. - The audit committee, composed of three independent non-executive directors, ensures the integrity and accuracy of the company's financial statements[127]. - The company has established specific committees, including the audit, remuneration, nomination, and reward committees, to oversee various aspects of corporate governance[125]. - The company aims to enhance board diversity by actively seeking suitable female candidates for board positions, despite not having appointed any female directors since its listing[143]. Risk Management - The company has established a comprehensive risk management framework, guided by a "three lines of defense" model[175]. - The risk management department, consisting of the Vice President of Finance and Senior Finance Manager, oversees the overall risk management framework[177]. - The internal audit function plays a crucial role in providing independent assurance on the effectiveness of the risk management and internal control systems[187]. - The company conducts semi-annual reporting on significant risks identified from operational subsidiaries[186]. Shareholder Communication - The company maintains communication with shareholders through multiple channels and has a shareholder communication policy to address shareholder concerns effectively[190]. - All resolutions presented at the shareholders' meeting must be voted on, with results published on the company's and the stock exchange's websites after the meeting[192]. - Shareholders holding at least 10% of the paid-up capital have the right to request the board to convene a special meeting within two months of the request[196].

JBM (Healthcare) Limited 健倍苗苗 （保 健 ）有限公司 2021 INTERIM REPORT 中期報告 Interim Report 2021 健倍苗苗（保健）有限公司 於開曼群島註冊成立的有限公司 股份代號 : 2161 Stock Code: 2161 二零二一年中期報告 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目錄 | | | | | | | | | | | | | | | | | | | | | | | | | | 2 | | 公司資料 | | | | | | | | | | | | | | | | 3 | | 財務摘要 | | | | | | ...

健倍苗苗（保健）有限公司 於開曼群島註冊成立的有限公司 股份代號 : 2161 Movement inspires 年報 2021 公司資料 董事會 執行董事 黃一偉先生 （行政總裁） 朱家榮博士 非執行董事 岑廣業先生 （主席） 嚴振亮先生 楊國晉先生 獨立非執行董事 陳錦釗先生 陸庭龍先生 劉述理先生 審核委員會 陳錦釗先生 （主席） 陸庭龍先生 劉述理先生 薪酬委員會 陸庭龍先生 （主席） 嚴振亮先生 陳錦釗先生 劉述理先生 提名委員會 岑廣業先生 （主席） 陳錦釗先生 陸庭龍先生 劉述理先生 授權代表 黃一偉先生 朱家榮博士 公司秘書 歐敏兒女士 註冊辦事處 Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Islands 香港總部及主要營業地點 香港 九龍觀塘 觀塘道388號 創紀之城 1期1座 23樓2303-07室 股份過戶登記總處 Conyers Trust Company (Cayman) Limited Cricket Square Hutchins Drive PO Box 2681 Grand ...